| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62ba5eda2d634cad2e4efeea59685fe3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-10 |
| filingDate |
2021-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d36926ff7732641e21c9e370c3a99da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1baf0c6627e0dbf50c9bbb376fb42706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a11be6871abd2665aeeac8ffe225bbd |
| publicationDate |
2021-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113082013-A |
| titleOfInvention |
Pharmaceutical uses of Napabucasin |
| abstract |
The pharmaceutical use of Napabucasin relates to its application in the preparation of antibacterial drugs, and the bacteria are Gram-negative bacteria, Gram-positive bacteria or fungi. Napabucasin has good antibacterial activity against standard sensitive Helicobacter pylori, clinical sensitive and resistant Helicobacter pylori, etc. The minimum inhibitory concentration ranges from 0.016 to 0.125 μg/mL. Helicobacter pylori has a good killing effect, which is stronger than that of metronidazole. Napabucasin is not easy to produce drug resistance in the process of anti-Helicobacter pylori, and has a strong killing effect on Helicobacter pylori colonization in the stomach of mice. Its single use or combined use with omeprazole is stronger than the standard triple therapy. In addition, it exhibited the same efficiency of killing Candida albicans as fluconazole in a systemic infection model of Candida albicans infected mice. |
| priorityDate |
2021-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |